Skip to content

Glaukos GKOS Debt conversion inducement expense

Debt conversion inducement expense at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$4.09M
Glaukos logo
GlaukosGKOS
$18.01M
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$4.09M
AST SpaceMobile logo
AST SpaceMobileASTS
$88.65M
Royal Caribbean Group logo
Royal Caribbean GroupRCL
$0-100%
Oscar Health logo
Oscar HealthOSCR
$3.33M

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:InducedConversionOfConvertibleDebtExpense.

The official record: Glaukos’s 10-Q, filed August 4, 2025, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's debt conversion inducement expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's debt conversion inducement expense?
Glaukos (GKOS) reported debt conversion inducement expense of $18.01M in Q2 2024.
What does debt conversion inducement expense mean?
Costs associated with incentivizing holders of convertible debt to convert their holdings into equity before the scheduled maturity date. This typically involves offering additional shares or cash payments to accelerate the conversion process.